These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30822450)

  • 21. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
    Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
    Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Murine Pneumonia Virus Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus from an Added Gene Is Highly Attenuated and Immunogenic in Rhesus Macaques.
    Brock LG; Liu X; Liang B; Lingemann M; Liu X; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Built-In CpG Adjuvant in RSV F Protein DNA Vaccine Drives a Th1 Polarized and Enhanced Protective Immune Response.
    Ma Y; Jiao YY; Yu YZ; Jiang N; Hua Y; Zhang XJ; Fu YH; Peng XL; Zheng YP; Anderson LJ; He JS
    Viruses; 2018 Jan; 10(1):. PubMed ID: 29342954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD4
    Schneider-Ohrum K; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; Cheng LI; O'Day T; Cayatte C
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV.
    Turner TM; Jones LP; Tompkins SM; Tripp RA
    J Virol; 2013 Oct; 87(19):10792-804. PubMed ID: 23903841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.
    Taleb SA; Al Thani AA; Al Ansari K; Yassine HM
    Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1817-1827. PubMed ID: 29876771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA vaccine encoding central conserved region of G protein induces Th1 predominant immune response and protection from RSV infection in mice.
    Hua Y; Jiao YY; Ma Y; Peng XL; Fu YH; Zheng YP; Hong T; He JS
    Immunol Lett; 2016 Nov; 179():95-101. PubMed ID: 27688078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection.
    Qiao L; Zhang Y; Chai F; Tan Y; Huo C; Pan Z
    Antiviral Res; 2016 Jul; 131():131-40. PubMed ID: 27154395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Formulation of the respiratory syncytial virus fusion protein with a polymer-based combination adjuvant promotes transient and local innate immune responses and leads to improved adaptive immunity.
    Sarkar I; Garg R; van Drunen Littel-van den Hurk S
    Vaccine; 2016 Sep; 34(42):5114-5124. PubMed ID: 27591951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical evaluation of bacterially produced RSV-G protein vaccine: Strong protection against RSV challenge in cotton rat model.
    Fuentes S; Klenow L; Golding H; Khurana S
    Sci Rep; 2017 Feb; 7():42428. PubMed ID: 28186208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
    Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
    Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults.
    Ye X; Iwuchukwu OP; Avadhanula V; Aideyan LO; McBride TJ; Ferlic-Stark LL; Patel KD; Piedra FA; Shah DP; Chemaly RF; Piedra PA
    Front Immunol; 2019; 10():706. PubMed ID: 30984206
    [No Abstract]   [Full Text] [Related]  

  • 36. RSV fusion (F) protein DNA vaccine provides partial protection against viral infection.
    Wu H; Dennis VA; Pillai SR; Singh SR
    Virus Res; 2009 Oct; 145(1):39-47. PubMed ID: 19540885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nasal immunization with RSV F and G protein fragments conjugated to an M cell-targeting ligand induces an enhanced immune response and protection against RSV infection.
    Khan IU; Huang J; Li X; Xie J; Zhu N
    Antiviral Res; 2018 Nov; 159():95-103. PubMed ID: 30290196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology.
    Blanco JC; Boukhvalova MS; Pletneva LM; Shirey KA; Vogel SN
    Vaccine; 2014 Mar; 32(13):1495-500. PubMed ID: 24252693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
    August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
    Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.